An Executive Informational Overview (EIO) is now available on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), a specialty biotech pharmaceutical company focused on developing FDA-approved synthetic compounds targeting the endocannabinoid system (ECS) of the human body. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Snapshot of FSD Pharma Inc.
FSD Pharma Inc. (“FSD” or “the Company”) is a specialty biotech pharmaceutical company focused on developing FDA-approved synthetic compounds targeting the endocannabinoid system (ECS) of the human body. The Company is addressing certain diseases of the central nervous system as well as autoimmune disorders of the skin, gastrointestinal (GI) tract, and musculoskeletal system.
Following FSD’s 2Q19 acquisition of Prismic Pharmaceuticals (“Prismic”)—forming part of the Company’s BioSciences subsidiary—FSD is also seeking to tackle the opioid crisis by developing non-addictive prescription drugs to treat pain and inflammation using a ultramicronized formulation of palmitolylethonalamide (PEA) or ultramicronized PEA. PEA interacts with endocannabinoid receptors throughout the body and is a naturally occurring anti-inflammatory. It’s anti-inflammatory and analgesic effects may help overcome the problem created by prolonged opioid use as it reduces the development of opioid tolerance and potentiates drug efficacy, thus allowing for the use of lower doses of opioids.
FSD’s other subsidiary, FV Pharma, is a Licensed Producer under Canada’s Cannabis Act and Regulations, having received its Cultivation License on October 13, 2017 and its full Sale for Medical Purposes License on June 21, 2019. The Company is licensed to cultivate cannabis at its Cobourg, Ontario facility, reporting approximately C$260,000 in medical cannabis sales during 4Q19.
Key Points
- FSD seeks to target diseases/syndromes where synthetic compounds, including cannabinoids that target the ECS, may prove more effective than alternatives. Its lead candidate, FSD201 ultramicronized PEA, recently received approval to initiate Phase 1 first-in-human safety and tolerability trials.
- As evidence of cannabis’ benefits mounts, so does the global pharmaceutical industry’s interest. Their entry not only brings significant investment and research capabilities but could accelerate public understanding and confidence in synthetic compounds, including cannabinoids that target the ECS as an option for a range of ailments, fueling the industry’s growth.
- On January 9, 2020, FSD’s shares began trading on the NASDAQ Capital Market under the ticker symbol HUGE, joining a select group of 12 Canadian-domiciled cannabis companies that trade in the U.S. on either the NYSE or NASDAQ markets.
- The Company’s worldwide patent portfolio is protected for ten more years, with ultramicronized composition-of-matter and use features patents extending though 2029 to 2034.
- FSD’s management team is advised by an experienced Board of Directors and Scientific Advisory Board, who provide enormous insight and value.
- As of December 31, 2019, FSD had C$7.9 million in cash.
*******************************************
Visit our Corporate Profile and Key Investment Highlights pages
for the latest research on FSD Pharma Inc.
*******************************************